Understanding Meropenem and Antibiotic Tiers
Meropenem belongs to the carbapenem class of antibiotics, which are often reserved as a last line of defense against serious bacterial infections [1.3.2]. These β-lactam antibiotics have a broad spectrum of activity, meaning they are effective against a wide range of Gram-positive and Gram-negative bacteria [1.3.4, 1.4.5]. Meropenem functions by inhibiting the synthesis of the bacterial cell wall, which leads to cell death [1.5.3, 1.5.4]. For years, it has been a go-to treatment for complex infections, including those in hospitalized patients.
However, the widespread use and overuse of antibiotics have driven the evolution of bacteria that can survive these powerful drugs [1.3.2]. The most significant threat concerning carbapenems is the emergence of Carbapenem-Resistant Enterobacteriaceae (CRE). These bacteria produce enzymes called carbapenemases that can break down meropenem and other carbapenems, rendering them ineffective [1.3.2, 1.3.4]. The CDC considers CRE an urgent public health threat [1.9.2].
The Rise of Carbapenem-Resistant Infections
When an infection does not respond to meropenem, it signifies a high level of antibiotic resistance. This resistance is primarily mediated by carbapenemase enzymes, which are categorized into Ambler classes A, B, and D [1.3.4]. Some of the most clinically significant carbapenemases include Klebsiella pneumoniae carbapenemase (KPC), New Delhi metallo-beta-lactamase (NDM), Verona integron-encoded metallo-beta-lactamase (VIM), and oxacillinase-48 (OXA-48) [1.3.2, 1.3.4]. Infections caused by bacteria producing these enzymes are associated with high mortality rates and require a new class of antibiotics that are considered "higher" or more advanced than meropenem [1.5.5].
Antibiotics 'Higher' Than Meropenem
Treating meropenem-resistant infections requires newer agents that can overcome these resistance mechanisms. The primary strategy has been to combine a β-lactam antibiotic with a novel β-lactamase inhibitor. This inhibitor protects the antibiotic from being destroyed by the carbapenemase enzyme [1.3.2].
Novel β-Lactam/β-Lactamase Inhibitor (BL/BLI) Combinations
These drugs are the frontline choice for many serious CRE infections [1.2.6].
-
Meropenem-vaborbactam (Vabomere®): This combination pairs meropenem with vaborbactam, a boronic acid-based β-lactamase inhibitor [1.5.5]. Vaborbactam effectively neutralizes Class A carbapenemases like KPC [1.5.3, 1.5.6]. It restores meropenem's activity against many KPC-producing CRE isolates [1.5.3]. It is indicated for complicated urinary tract infections (cUTI), including pyelonephritis [1.5.1, 1.5.2]. However, it is not active against metallo-β-lactamases (Class B) or OXA-type (Class D) carbapenemases [1.5.6].
-
Imipenem-cilastatin-relebactam (Recarbrio®): This drug combines the carbapenem imipenem (co-packaged with cilastatin to prevent its degradation in the kidneys) with relebactam, a novel diazabicyclooctane inhibitor [1.7.5]. Relebactam inhibits Class A (like KPC) and Class C β-lactamases [1.7.5]. This combination is used for hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VABP) and complicated intra-abdominal and urinary tract infections [1.7.1, 1.7.4]. Like meropenem-vaborbactam, it is not effective against metallo-β-lactamase (MBL) or OXA-48-producing bacteria [1.7.5].
-
Ceftazidime-avibactam (Avycaz®): This combines a third-generation cephalosporin, ceftazidime, with avibactam, another diazabicyclooctane inhibitor [1.2.3]. Avibactam is unique in that it inhibits Class A (KPC), Class C, and some Class D (OXA-48) enzymes [1.2.3, 1.3.2]. This gives it a broader spectrum against different types of CRE compared to the carbapenem-based combinations. It is a first-line option for many serious CRE infections but is not effective against MBL-producing strains [1.2.1, 1.2.6]. For MBL-producing infections, a combination of ceftazidime-avibactam plus aztreonam is sometimes considered [1.2.6].
A Novel Cephalosporin: The 'Trojan Horse' Antibiotic
- Cefiderocol (Fetroja®): Cefiderocol represents a completely new approach. It is a siderophore cephalosporin, which means it has a side chain that binds to iron [1.6.2, 1.6.5]. Bacteria have active iron transport systems to acquire this essential nutrient. Cefiderocol hijacks these systems to gain entry into the bacterial cell, acting like a "Trojan horse" [1.6.2]. This unique entry mechanism allows it to bypass resistance mechanisms like porin channel mutations and efflux pumps [1.6.2]. Critically, cefiderocol is stable against hydrolysis by all Ambler classes of carbapenemases, including serine-based enzymes (KPC, OXA) and metallo-β-lactamases (NDM, VIM, IMP) [1.6.6]. This gives it the broadest spectrum of activity against multi-drug resistant Gram-negative bacteria, making it a crucial option for infections where other new agents may fail [1.6.1, 1.6.4]. It has no activity against Gram-positive or anaerobic bacteria [1.6.1].
Comparison of Advanced Antibiotics
| Feature | Meropenem (Carbapenem) [1.3.2] | Meropenem-vaborbactam [1.5.3] | Imipenem-cilastatin-relebactam [1.7.5] | Ceftazidime-avibactam [1.2.3] | Cefiderocol [1.6.2, 1.6.6] |
|---|---|---|---|---|---|
| Drug Class | Carbapenem | Carbapenem / β-lactamase inhibitor | Carbapenem / β-lactamase inhibitor | Cephalosporin / β-lactamase inhibitor | Siderophore Cephalosporin |
| Mechanism of Action | Inhibits cell wall synthesis | Meropenem inhibits cell wall; vaborbactam inhibits β-lactamase | Imipenem inhibits cell wall; relebactam inhibits β-lactamase | Ceftazidime inhibits cell wall; avibactam inhibits β-lactamase | Binds iron to enter cell, then inhibits cell wall synthesis; stable against β-lactamases |
| Activity vs. KPC | No (Resistant) | Yes | Yes | Yes | Yes |
| Activity vs. OXA-48 | No (Resistant) | No | No | Yes | Yes |
| Activity vs. MBLs | No (Resistant) | No | No | No | Yes |
Authoritative Link: CDC Page on Carbapenem-Resistant Enterobacteriaceae (CRE)
Conclusion
The question of "what antibiotic is higher than meropenem?" doesn't have a single answer but rather points to a new tier of advanced antimicrobial agents. The choice depends on identifying the specific resistance mechanism of the infecting bacteria. For infections caused by KPC-producing CRE, options like meropenem-vaborbactam and imipenem-cilastatin-relebactam are effective [1.2.1]. Ceftazidime-avibactam offers broader coverage that includes OXA-48 producers [1.2.3]. For the most difficult-to-treat infections, especially those caused by metallo-β-lactamase (MBL) producers or bacteria with multiple resistance mechanisms, the novel siderophore cephalosporin cefiderocol is often the most potent option available [1.6.4, 1.6.6]. The development of these drugs marks a critical step forward in the ongoing battle against antimicrobial resistance.
